Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured Whitepaper
Key Success Factors to Building a Best Practice Medical Affairs Organization
Learn More >
Featured Whitepaper
Building Peak Performance Go-to-Market Operations: Capturing the Value of Medical Innovation in a Fast-Changing Landscape
Learn More >
Blog
Medical Affairs Metamorphosis, Part I: Trends Driving Major Change and What They Mean for Medical Affairs
Blog
The CNS Market: 2021 Review & Predictions for 2022
Whitepaper
Towards Cancer Cures and Chronic Management: Key Trends and Their Commercial Implications
Blog
What does COMPASS Pathways’ recent data on psilocybin mean for psychedelic therapies?
Blog
Towards Cancer Cures and Chronic Management: Key Trends and Their Commercial Implications
Whitepaper
Launching a First Product in Europe: The Supply Chain Perspective
Whitepaper
Summary of Blue Matter Breakfast Club #10: Patient Identification in Rare Diseases
Blog
12 Pitfalls in Europe: Pitfall #5 – Thinking your list price won’t cross borders
Blog
12 Pitfalls in Europe: Pitfall #4 – Believing EMA marketing authorization = patient access
Blog
12 Pitfalls in Europe: Pitfall #3 – Missing the Opportunity of a Conditional Marketing Authorization
Blog
12 Pitfalls in Europe: Pitfall #2 – Not Realizing Europe May Have Its Own Clinical Endpoints in Mind
Blog
12 Pitfalls in Europe: Pitfall #1 – Not knowing what it takes to “go it alone”
Whitepaper
Panel Discussion Summary: The Renaissance of Psychedelics in CNS Medicine
Whitepaper
Spinal Muscular Atrophy: Outlook and Implications for Biopharma (Part 2)
Whitepaper
Spinal Muscular Atrophy: A Rare Disease with a Complex Treatment Landscape (Part 1)
Blog
Spinal Muscular Atrophy: Outlook and Implications for Biopharma (Part 2)
